| Citation: |
ZHAO Rongchang, YU Wenyan, FENG Yuxin, ZHANG Wanli, ZHU Chunrong. Comparison of Efficacy Between S-1 and Capecitabine/Fluorouracil on Advanced Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2019, 46(12): 1123-1130. DOI: 10.3971/j.issn.1000-8578.2019.19.0138
|
To conduct a meta-analysis on the data of S-1 and capecitabine or fluorouracil in the treatment of advanced colorectal cancer, to demonstrate the feasibility of S-1 replacing capecitabine or fluorouracil.
We searched published literature in the PubMed, Cochrane Library, Embase and CNKI databases, and searched for controlled trials at the Clinical Trials Center (https://www.clinicaltrials.gov/). The data extraction and quality evaluation were conducted according to Cochrane Handbook 5.1.0, and RevMan 5.3 software was used for the meta-analysis of relevant case-control studies.
The data of 3462 patients from 11 randomized controlled trials were included. Compared with the capecitabine/fluorouracil regimen, OS was improved in the S-1 treatment group, but there was no statistically significant difference in PFS, DCR or ORR. The incidence of diarrhea, renal insufficiency and hand-foot syndrome in the S-1 group was lower than that in the control group. But the incidence of platelet reduction in the S-1 group was higher than that in the control group at a reasonable contrast dose.
S-1 has a certain therapeutic advantage after replacing capecitabine or fluorouracil in conventional chemotherapy on advanced colorectal cancer.
| [1] |
Schoffski P. The modulated oral fluoropyrimidine prodrug S-1, and its use in gastrointestinal cancer and other solid tumors[J]. Anticancer Drugs, 2004, 15(2): 85-106. http://cn.bing.com/academic/profile?id=3179595161612f671451d707605ac11e&encoded=0&v=paper_preview&mkt=zh-cn
|
| [2] |
Meta-analysis Group In Cancer, Piedbois P, Rougier P, et al. Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer[J]. J Clin Oncol, 1998, 16(1): 301-308. doi: 10.1200/JCO.1998.16.1.301
|
| [3] |
Cascinu S. Oral treatment for gastric cancer: new choices, better choices?[J]. Lancet Oncol, 2008, 9(3): 188-189. doi: 10.1016/S1470-2045(08)70042-1
|
| [4] |
Cervantes A, Roda D, Tarazona N, et al. Current questions for the treatment of advanced gastric cancer[J]. Cancer Treat Rev, 2013, 39(1): 60-67. doi: 10.1016/j.ctrv.2012.09.007
|
| [5] |
Pieters A, Laurent S, Dero I, et al. The role of oral fluoropyrimidines in the treatment of advanced gastric cancer[J]. Acta Gastroenterol Belg, 2008, 71(4): 361-366. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_f268c94982fec45cd302ba5dc7284105
|
| [6] |
沈旭东, 庄志祥, 甘蕾, 等.每周脂质体紫杉醇或奥沙利铂联合替吉奥方案治疗老年晚期胃癌的疗效及安全性分析[J].肿瘤防治研究, 2016, 43(5): 400-403. doi: 10.3971/j.issn.1000-8578.2016.05.017
Shen XD, Zhuang ZX, Gan L, et al. Efficacy and safety of weekly liposome-paclitaxel or oxaliplatin combined with tegafur on elderly advanced gastric cancer[J]. Zhong Liu Fang Zhi Yan Jiu, 2016, 43(5): 400-403. doi: 10.3971/j.issn.1000-8578.2016.05.017
|
| [7] |
Shirasaka T. Development history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistas[J]. Jpn J Clin Oncol, 2009, 39(1): 2-15. http://d.old.wanfangdata.com.cn/OAPaper/oai_pubmedcentral.nih.gov_2639406
|
| [8] |
Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration[J]. Ann Intern Med, 2009, 151(4): W65-94. http://d.old.wanfangdata.com.cn/OAPaper/oai_doaj-articles_fdde0aeaf4039c7452595b26180bc84b
|
| [9] |
Hamaguchi T, Shimada Y, Mizusawa J, et al. Capecitabine versus S-1 as adjuvant chemotherapy for patients with stage Ⅲ colorectal cancer (JCOG0910): an open-label, non-inferiority, randomised, phase 3, multicentre trial[J]. Lancet Gastroenterol Hepatol, 2018, 3(1): 47-56. doi: 10.1016/S2468-1253(17)30297-2
|
| [10] |
Kwakman JJM, Simkens LHJ, van Rooijen JM, et al. Randomized phase Ⅲ trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group[J]. Ann Oncol, 2017, 28(6): 1288-1293. doi: 10.1093/annonc/mdx122
|
| [11] |
Kim ST, Hong YS, Lim HY, et al. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial[J]. BMC Cancer, 2014, 14: 883. doi: 10.1186/1471-2407-14-883
|
| [12] |
Kim JH, Zang DY, Chung IJ, et al. A Muti-center, Randomized Phase Ⅱ Study of Oxaliplatin and S-1 versus Capecitabine and Oxaliplatin in Patients with Metastatic Colorectal Cancer[J]. J Cancer, 2015, 6(10): 1041-1048. doi: 10.7150/jca.12819
|
| [13] |
Muro K, Boku N, Shimada Y, et al. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study)[J].Lancet Oncol, 2010, 11(9): 853-860. doi: 10.1016/S1470-2045(10)70181-9
|
| [14] |
王凤歧.替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌的临床对比[J].世界最新医学信息文摘(电子版), 2017, 17(11): 96-97. http://d.old.wanfangdata.com.cn/Periodical/yiyqy201420213
Wang FQ. The Clinical Comparison of Tigio or Capecitabine Combined with Oxaliplatin in the Treatment of Advanced Colorectal Cancer[J]. Shi Jie Zui Xin Yi Xue Xin Xi Wen Zhai (Dian Zi Ban), 2017, 17(11): 96-97. http://d.old.wanfangdata.com.cn/Periodical/yiyqy201420213
|
| [15] |
陈其珠.替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌效果对比分析[J].临床医药文献电子杂志, 2017, 4(103): 20396. http://d.old.wanfangdata.com.cn/Periodical/henanykdx201305033
Chen QZ. Comparative analysis of the efficacy of tigapetabine or capecitabine combined with oxaliplatin in the first-line treatment of advanced colorectal cancer[J]. Lin Chuang Yi Yao Wen Xian Dian Zi Za Zhi, 2017, 4(103): 20396. http://d.old.wanfangdata.com.cn/Periodical/henanykdx201305033
|
| [16] |
杨晓利, 王峰, 夏金, 等.替吉奥或卡培他滨联合奥沙利铂一线治疗晚期结直肠癌效果对比分析[J].郑州大学学报(医学版), 2013, 48(5): 688-690. http://d.old.wanfangdata.com.cn/Periodical/henanykdx201305033
Yang XL, Wang F, Xia J, et al. Retrospective study on S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with advanced colorectal cancer[J]. Zhengzhou Da Xue Xue Bao(Yi Xue Ban), 2013, 48(5): 688-690. http://d.old.wanfangdata.com.cn/Periodical/henanykdx201305033
|
| [17] |
郭浩.晚期结直肠癌患者行替吉奥或卡培他滨联合奥沙利铂一线治疗的临床疗效对比分析[J].现代消化及介入诊疗, 2016, 21(5): 765-767. doi: 10.3969/j.issn.1672-2159.2016.05.035
Guo H. Comparative analysis of clinical efficacy of tigapetabine or capecitabine combined with oxaliplatin in advanced colorectal cancer patients[J]. Xian Dai Xiao Hua Ji Jie Ru Zhen Liao, 2016, 21(5): 765-767. doi: 10.3969/j.issn.1672-2159.2016.05.035
|
| [18] |
张瑞亮, 李文见, 姜统杰.奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者疗效对比[J].癌症进展, 2017, 15(2): 196-198. http://d.old.wanfangdata.com.cn/Periodical/azjz201702027
Zhang RL, Li WJ, Jiang TJ. The effect of oxaliplatin combined with capecitabine or S-1 in patients with advanced colon cancer[J]. Ai Zheng Jin Zhan, 2017, 15(2): 196-198. http://d.old.wanfangdata.com.cn/Periodical/azjz201702027
|
| [19] |
Yamada Y, Takahari D, Matsumoto H, et al. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial[J]. Lancet Oncol, 2013, 14(13): 1278-1286. doi: 10.1016/S1470-2045(13)70490-X
|
| [1] | WANG Ya'nan, LU Wenping, MEI Heting, CUI Yongjia, ZHUO Zhili. Risk of Recurrence or Metastasis of Breast Cancer by LNG-IUS: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(8): 786-791. DOI: 10.3971/j.issn.1000-8578.2022.21.1536 |
| [2] | XIA Lin, YU Guozheng, TANG Jing. Diagnostic Value of Circular RNAs for Colorectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(9): 864-870. DOI: 10.3971/j.issn.1000-8578.2021.21.0069 |
| [3] | LIANG Tong, LIU Huajie, DA Mingxu. Metabolic Syndrome and Risk of Gastric Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2021, 48(3): 268-273. DOI: 10.3971/j.issn.1000-8578.2021.20.0957 |
| [4] | SHAO Lihua, ZHANG Qiuning, LUO Hongtao, YANG Zhen, LIU Ruifeng, TIAN Jinhui, LI Zheng, WANG Xiaohu, YANG Kehu. Carbonions and Proton Therapy for Hepatocellular Carcinoma: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2020, 47(5): 358-366. DOI: 10.3971/j.issn.1000-8578.2020.19.1158 |
| [5] | JIAN Yaowen, WANG Lei, Liu Ye, HE Mingyan, RANG Weiqing. A Meta-analysis of Dietary Vitamin Consumption and Risk of Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2020, 47(2): 108-111. DOI: 10.3971/j.issn.1000-8578.2020.19.0007 |
| [6] | KUANG Yuhui, CHEN Xinju, XU Fangbiao. Meta-analysis of Efficacy and Safety of Jinlong Capsule Combined with Chemoradiotherapy on Liver Metastases[J]. Cancer Research on Prevention and Treatment, 2020, 47(1): 63-69. DOI: 10.3971/j.issn.1000-8578.2020.19.0619 |
| [7] | CAO Lingzhi, XIE Jianping, PENG Xiaodong, WEN Huling, LI Suping, YANG Yaowu. Association of Iodine Intake and Iodine-enriched Food with Risk of Thyroid Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2016, 43(7): 616-622. DOI: 10.3971/j.issn.1000-8578.2016.07.015 |
| [8] | LIU Min, SONG Yang, YANG Fuguo. Effect of Food Intake on Risk of Rectal Cancer: A Meta-analysis[J]. Cancer Research on Prevention and Treatment, 2014, 41(12): 1343-1347. DOI: 10.3971/j.issn.1000-8578.2014.12.020 |
| [9] | Ma Jun, Nie Shengnan, Shi Benling, Zuo Wenshu. Meta Analysis on Relationship between Soyfood and Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2012, 39(02): 218-221. DOI: 10.3971/j.issn.1000-8578.2012.02.025 |
| [10] | QIU Yue-feng, CAI Lin. Meta-analysis on Relationship between Body Mass Index and Lung Cancer Risk[J]. Cancer Research on Prevention and Treatment, 2010, 37(02): 218-222. DOI: 10.3971/j.issn.1000-8578.2010.02.025 |
This work is licensed under a Creative Commons Attribution 3.0 License.
Copyright © Editorial Department of Cancer Prevention Research 鄂公网安备 42011102005013号 鄂ICP备2022015867号
Supported by: Beijing Renhe Information Technology Co., Ltd. 
DownLoad: